Logo Geneseeq
  • Products
    • Solid Tumors
      • Pan-Cancer
      • Cancer Type-Specific
      • Minimal Residual Disease
    • Hematologic Malignancies
      • Pan-Cancer
      • Cancer Type-Specific
    • Cancer Early Detection
    • Hereditary Cancers
  • Services
    • Central Lab Testing
    • Local Testing Solutions
      • IVD Kit Solutions
      • RUO Kit Solutions
    • Research Services
      • DNA Sequencing
      • RNA Sequencing
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
    • Newsroom
    • Geneseeq Blogs
  • Join Us
  • Contact Us
  • Search

December 3, 2024

GENESEEQ’S NGS LIQUID BIOPSY KIT MARKS THE FIRST TO ENTER NMPA’S SPECIAL REVIEW AND APPROVAL OF INNOVATIVE MEDICAL DEVICE

by GENESEEQ

July 3, 2024

Geneseeq partners with Jiangsu Vcare PharmaTech to develop a CDx for NTRK inhibitor in China.

by GENESEEQ

January 3, 2024

FDA Grants Breakthrough Device Designation for Geneseeq’s Multi-cancer Early Detection Solution

by GENESEEQ

August 22, 2023

Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer

by Geneseeq

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer

by Geneseeq

July 19, 2022

Geneseeq, Brazilian Hospital Partner on Co-establishment of In-house NGS Lab

by GENESEEQ

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info@geneseeq.ca

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2026 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences

    FDA Cleared IVD kit